Phase II trial of temozolomide in patients with cisplatin-refractory germ cell tumors

被引：10

作者：

Kondagunta, GV

Bacik, J

Schwartz, L

Sheinfeld, J

Bajorin, D

Vuky, J

Marion, S

Mazumdar, M

Bosl, GJ

Motzer, RJ

机构：

[1] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA

[2] Mem Sloan Kettering Canc Ctr, Dept Radiol, New York, NY 10021 USA

[3] Mem Sloan Kettering Canc Ctr, Dept Urol, New York, NY 10021 USA

[4] Mem Sloan Kettering Canc Ctr, Dept Biostat Epidemiol & Stat, New York, NY 10021 USA

来源：

INVESTIGATIONAL NEW DRUGS | 2004年 / 22卷 / 02期

关键词：

temozolomide; germ cell tumor; nonseminoma; cisplatin-refractory; phase II;

D O I：

10.1023/B:DRUG.0000011794.21608.59

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Fourteen patients with cisplatin-refractory germ cell tumors (GCT) were treated with temozolomide on a phase II trial. Temozolomide was given orally at 150 mg/m(2)/day on days 1-5. The cycle length was 28 days. No patient experienced a grade 3 or 4 toxicity, and none of the 14 evaluable patients achieved a complete or partial response. Temozolomide is not efficacious in the treatment of cisplatin-refractory GCT patients.

引用

页码：177 / 179

页数：3

共 50 条

[21] A phase II trial of paclitaxel in refractory germ cell tumors
Sandler, AB
Cristou, A
Fox, S
Williams, SD
Nichols, CR
Turns, M
Roth, BJ
CANCER, 1998, 82 (07) : 1381 - 1386
[22] Phase II trial of gemcitabine in refractory germ cell tumors
Einhorn, LH
Stender, MJ
Williams, SD
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (02) : 509 - 511
[23] Combination chemotherapy with gemcitabine, oxaliplatin and paclitaxel in patients with cisplatin-refractory or relapsed germ cell tumors (gct)
Oechsle, K.
Bokemeyer, C.
Honecker, F.
Mayer, F.
Waller, C. F.
Boehlke, I.
Hartmann, J. T.
Kollmannsberger, C.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
[24] A phase II trial of weekly irinotecan in cisplatin-refractory esophageal cancer
Burkart, Christof
Bokemeyer, Carsten
Klump, Bodo
Pereira, Philippe
Teichmann, Reinhard
Hartmann, Joerg Thomas
ANTICANCER RESEARCH, 2007, 27 (4C) : 2845 - 2848
[25] Sunitinib in patients with multiply relapsed or cisplatin-refractory germ cell cancer: A CLOG/GTCSG cooperative phase II study.
Kollmannsberger, C. K.
Oechsle, K.
Cheng, T.
Mayer, F.
Czaykowski, P.
Winquist, E.
Wood, L.
Fenner, M.
Chi, K. N.
Bokemeyer, C.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[26] PHASE-II TRIAL OF MITOGUAZONE IN PATIENTS WITH REFRACTORY GERM-CELL TUMORS
CHUN, H
BOSL, GJ
CANCER TREATMENT REPORTS, 1985, 69 (04): : 461 - 462
[27] Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a phase II study of the German Testicular Cancer Study Group
C Kollmannsberger
O Rick
H Klaproth
T Kubin
H G Sayer
M Hentrich
M Welslau
F Mayer
M Kuczyk
C Spott
L Kanz
C Bokemeyer
British Journal of Cancer, 2002, 87 : 729 - 732
[28] Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a phase II study of the German Testicular Cancer Study Group
Kollmannsberger, C
Rick, O
Klaproth, H
Kubin, T
Sayer, HG
Hentrich, M
Welslau, M
Mayer, F
Kuczyk, M
Spott, C
Kanz, L
Bokemeyer, C
BRITISH JOURNAL OF CANCER, 2002, 87 (07) : 729 - 732
[29] Oxaliplatin-Gemcitabine combination for patients with cisplatin-refractory germ cell tumor
De Giorgi, Ugo
Rosti, Giovanni
Aieta, Michele
Testore, Franco
Fornarini, Giuseppe
Burattini, Luciano
Papiani, Giorgio
Zumaglini, Federica
Marangolo, Maurizio
ANNALS OF ONCOLOGY, 2005, 16 : 80 - 80
[30] Brief Report: Phase II Multicenter Study of Temozolomide in Patients with Cisplatin-Resistant Germ Cell Tumors
Maroto, P.
Huddart, R.
Garcia del Muro, X.
Horwich, A.
Paz Ares, L.
Aparicio, J.
Germa-Lluch, J. R.
ONCOLOGY, 2011, 80 (3-4) : 219 - 222

← 1 2 3 4 5 →